BELLBERRY LIMITED RELEASES CLINICAL TRIAL ACTIVITY REPORT 2024 Nation’s largest reviewer of clinical trials across Australia through Human Research Ethics Committees (HRECs)
With
Kylie Sproston, Chief Executive Officer
Bellberry Limited, Adelaide
AUSTRALIAN HEALTH JOURNAL SEGMENT
Filmed in Adelaide | May 2025
Released in the week of International Clinical Trials Day 2025
Established in 2004, Bellberry is a Adelaide-based national, not-for-profit organisation that provides streamlined scientific and ethical reviews of human research. It is the 2025 winner of the Championing Health Award in the Telstra Best of Business Awards.
Australian Health Journal spoke with Bellberry Limited CEO, Kylie Sproston on the organisation and the findings in activity documented in the Clinical Trial Activity Report (CTAR) 2024.
Global investment in Australian clinical trials is strong, with two thirds of Australian clinical trials, reviewed by Bellberry, funded by international companies according to the CTAR.
Bellberry is Australia’s largest ethics and scientific reviewer of research involving humans reviewing approximately 40% of CTN (Clinical Trial Notification) trials in Australia.
Every year since 2019, Bellberry has released its Clinical Trial Activity Report (CTAR) to coincide with International Clinical Trials Day on 20 May. The CTAR describes the portfolio of research conducted in the prior year with Bellberry oversight.
Bellberry CEO, Kylie Sproston, says the 2024 data shows that Australia is uniquely placed to attract worldwide investment in clinical trials activity due to the high quality of its healthcare institutions and researchers.
“The 2024 Clinical Trial Activity Report shows that early phase trial activity remains a key strength with significant and continued growth over the last six years,” said Ms Sproston.
“The USA is the largest driver of early phase trials conducted in Australia, with Australia coming second and China third. Other top 10 countries include Germany, South Korea, Switzerland, the UK, Canada, France and Japan,” she said.
“Almost 50 per cent of the trials that Bellberry reviews are First in Human or Phase 1 trials, highlighting Australia’s strong reputation for this skilled and complex type of research.”
In 2024, oncology accounted for more than a quarter of the studies reviewed by Bellberry, while non-clinical trials made up more than 15 per cent of Bellberry reviews.
“Interestingly, we have seen a doubling of the number of social science research activities that Bellberry has reviewed in the last six years from 5% to 10% of total reviews,” said Ms Sproston.
“Australia’s capacity to support the full clinical development pathway is highlighted by the representation of trials in the 2024 CTAR from FIH through to Phase 4, devices, observational, qualitative, social science, registry, audit, and evaluation.”
The CTAR can be downloaded from the Bellberry Limited website.
Source: Adapted from Bellberry Limited News Story
-
Health-Tech Connections
Challenges in health care delivery have compounded, with clinical staff being exposed to the Omicron COVID variant. Reduced staffing has brought on its challenges to most already-strained state health care systems and the people working in them.
However, over the past 2 years of the pandemic, technology has played an increasing role on the front end for patients and consumers at home and clinicians in the medical setting. Much more is planned in technology that will deliver efficiency, reduce risk and make available new models of care. This has the potential to touch the working lives of all stakeholders and
recipients of care. -
ARCS Annual Conference 2019
Earlier this month, ARCS Australia held it’s Annual Conference at the International Convention Centre Sydney – ICC Sydney, with the theme of putting patients at the centre of healthcare. Uniquely, the conference included a number of patients who attended, presented or were referenced.
-
Metabolic health expert talks about healthy ageing
David Beard is a highly experienced Exercise Physiologist with a specialisation in metabolic health and healthy aging. He has spent over 40 years in this profession, even before exercise physiology was formally recognised as a discipline. His extensive background includes over a decade of working in aged care and a strong focus on adult health and fitness. David has authored a book on healthy aging and dedicated the last 10 to 12 years to advancing his expertise in metabolic health issues such as diabetes, weight loss, and inflammatory conditions. He is a co-owner of HFRC in Nedlands, Western Australia, where he has worked for nearly a decade.
